Category: 2CB

2C-B (full name 4-Bromo-2,5-dimethoxyphenethylamine) is a psychedelic compound first synthesized in 1974 by chemist Alexander Shulgin. It belongs to the 2C family of phenethylamines, which are known for producing psychedelic and entactogenic (emotional openness) effects.

Initially researched for its potential in psychotherapy, 2C-B later gained popularity in nightlife and psychedelic communities for its colorful visuals and empathogenic qualities.

Chemical and Pharmacological Profile

Class: Psychedelic phenethylamine.

Structure: Related to mescaline but modified with a bromine atom.

Mechanism of Action: Believed to work primarily through serotonin (5-HT2A) receptor agonism, similar to LSD and psilocybin, but with a distinct effect profile.

Effects of 2C-B
Psychedelic Visuals

Brightened colors and enhanced patterns.

Mild to moderate visual distortions at medium doses.

Less overwhelming than LSD or psilocybin, often described as “gentle psychedelia.”

Emotional and Social Effects

Increased empathy and connectedness.

Playful mood, laughter, and enhanced appreciation of music and touch.

Sometimes used in social or intimate settings for its entactogenic properties.

Cognitive Effects

Altered thought patterns.

Enhanced creativity.

At higher doses, more introspective and mystical experiences.

Dosage and Duration

Threshold Dose: ~5 mg.

Common Range: 15–25 mg orally.

Duration: 4–8 hours, depending on the dose and individual.

Compared to LSD or psilocybin, 2C-B is shorter-acting and often considered more controllable.

Risks and Side Effects

Although 2C-B is often described as less intense than classic psychedelics, risks still exist:

Short-Term Risks: Nausea, body tension, anxiety, or overstimulation.

Psychological Risks: Panic, confusion, or overwhelming visuals at high doses.

Physical Risks: Increased heart rate and blood pressure.

Like all psychedelics, set and setting play a critical role in shaping the experience.

Legal Status

2C-B is classified as a controlled substance in many countries, including the U.S., UK, and most of Europe. However, in some regions it remains in a legal gray area. Its legality is highly dependent on local drug laws.